Favipiravir, originally developed by Fujifilm Toyama Chemical, is an antiviral drug investigated for treating COVID-19.
It functions as a RNA-dependent RNA polymerase inhibitor, disrupting viral replication.
Favipiravir was initially designed for influenza but gained attention during the pandemic for its potential antiviral efficacy.